Advertisement
Cardiovascular
Subscribe to Cardiovascular
View Sample

FREE Email Newsletter

Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences

April 19, 2011 5:35 am | by Bio-Medicine.Org | News | Comments

SEATTLE, April 19, 2011 /- Omeros Corporation (NASDAQ: OMER ) today announced that research on mannan-binding lectin-associated serine protease-2 (MASP-2) has been published in the April 18, 2011 Early Online Edition of the Proceedings of the National Academy of Sciences (PNAS)....

Abaxis to Report Fourth Quarter and Fiscal Year 2011 Financial Results Thursday, April 28, 2011

April 19, 2011 5:35 am | by Bio-Medicine.Org | News | Comments

UNION CITY, Calif., April 19, 2011 /- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, has scheduled a conference call to discuss its financial results for the fourth quarter and fiscal year 2011, ended March 31, 2011. The call...

Cumberland Pharmaceuticals Announces New Product Addition With Hepatorenâ„¢ (ifetroban) Injection

April 19, 2011 3:33 am | by Bio-Medicine.Org | News | Comments

NASHVILLE, Tenn., April 19, 2011 /- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it has entered into an agreement to acquire the rights to ifetroban, a new Phase II...

Advertisement

CryoLife Announces Expiration of Go-Shop Period Related to its Proposed Acquisition of Cardiogenesis Corporation

April 18, 2011 6:35 am | by Bio-Medicine.Org | News | Comments

ATLANTA and IRVINE, Calif., April 18, 2011 /- CryoLife, Inc. (NYSE: CRY ), an implantable biological medical device and cardiovascular tissue processing company, today announced the expiration of the 20-day "go-shop" period that is part of its definitive agreement with Cardiogenesis...

Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient

April 18, 2011 6:34 am | by Bio-Medicine.Org | News | Comments

GAITHERSBURG, Md., April 18, 2011 /- Sigma-Tau Pharmaceuticals, Inc. is pleased to announce that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture L-asparaginase, the primary ingredient in the oncology medicine ONCASPAR® (pegaspargase)....

$210M Pfizer Deal Validates Small Firm

April 17, 2011 11:33 pm | by San Diego Business Journal | News | Comments

Robin Jackman, Zacharon's president and CEO, is the first to admit that there aren't too many people outside the biotech world who understand the science at the core of his small company.

Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and S...

April 17, 2011 10:34 pm | by Bio-Medicine.Org | News | Comments

MYSTIC, Conn. and DUBLIN, April 18, 2011 /- Amarin Corporation plc (Nasdaq: AMRN ), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from its ANCHOR trial for the Company's lead product...

Atrium Provides Grant to Establish Education Web Site at AtriumU.com

April 15, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

HUDSON, N.H., April 15, 2011 /- Atrium Medical Corporation has provided an educational grant to establish an educational web site, Atrium University, at www.AtriumU.com .  "Atrium has been proud to be the market leader in educational support for our customers," said Jeff McGill,...

Advertisement

New Test Spots Infections in Hours, Rather than Days

April 14, 2011 8:34 pm | by Massachusetts Institute of Technology | News | Comments

A startup has developed a device that uses magnetic particles to identify pathogens rapidly.

Tips For Enjoying A Healthy And Balanced Life

April 14, 2011 11:34 am | by Bio-Medicine.Org | News | Comments

SHENZHEN, China, April 14, 2011 /PRNewswire-Asia/ In today's modern high-tempo society, people always live a rapid pace of life . Fast food gets more and more popular especially in modern societies in which time is money. People also realize the importance of heath; they pay great...

Varian Medical Systems to Exhibit the Latest Digital Image Detectors, X-Ray Tubes and Cancer Treatment Technologies at the CMEF Show in Shenzhen, China

April 14, 2011 6:37 am | by Bio-Medicine.Org | News | Comments

SALT LAKE CITY, April 14, 2011 /- Booth #H1/E32 -- Varian Medical Systems (NYSE: VAR ) will exhibit a wide selection of X-ray tubes and flat panel image detectors for digital radiography (DR) at the China International Medical Equipment Fair (CMEF) meeting in Shenzhen, China, April 16-18,...

IDEV Announces Full Canadian Regulatory Approval for SUPERA VERITAS®

April 14, 2011 6:36 am | by Bio-Medicine.Org | News | Comments

WEBSTER, Texas, April 14, 2011 /- The Medical Devices Bureau of Health Canada has granted regulatory approval for the SUPERA VERITAS stent system for use in biliary and peripheral procedures.  IDEV's unique stent was previously available on a limited basis only, through the Special...

NeoStem's Subsidiary Progenitor Cell Therapy Receives FACT Accreditation for Its New Allendale, New Jersey Manufacturing Facility

April 13, 2011 6:36 am | by Bio-Medicine.Org | News | Comments

ALLENDALE, N.J., April 13, 2011 /- Progenitor Cell Therapy (PCT), a wholly owned subsidiary of NeoStem, Inc. (NYSE Amex: NBS ) and an internationally recognized cell therapy services and development company, announced today that it has, once again, demonstrated compliance with the...

Advertisement

According to the Journal of Advanced Nursing, RyMed Technologies' InVision-Plus® Excels at Minimizing Bacterial Growth In Vitro

April 13, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

FRANKLIN, Tenn., April 13, 2011 /- In the Journal of Advanced Nursing March issue, a comparative research evaluation of five needleless I.V. connectors tested by an independent laboratory showed that the RyMed InVision-Plus® (RYM-5001®) zero displacement connector best protected...

Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin

April 12, 2011 11:36 am | by Bio-Medicine.Org | News | Comments

EAST HANOVER, N.J., April 12, 2011 /- Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of Afinitor® (everolimus) tablets for the treatment of patients with...

Cluster's Founding Father Leads Firm

April 11, 2011 8:34 am | by San Diego Business Journal | News | Comments

David F. Hale, considered by many to be a founding father of San Diego's mighty biotechnology cluster, has taken the helm at Biocept, a cancer-focused diagnostic and laboratory services company that's getting ready to launch its first product in July.

Ligand to Achieve Profitability for 1st Time, Chief Says

April 10, 2011 11:34 pm | by San Diego Business Journal | News | Comments

Ligand Pharmaceuticals Inc. is on track for its first profitable year, said Rob McKay, the biotech's senior director of business development.

ViaCyte Takes Kyoto Laureate's Work to Next Level

April 10, 2011 11:33 pm | by San Diego Business Journal | News | Comments

A San Diego company that is working to bring to market a treatment for diabetes derived from embryonic stem cells is also working with Kyoto Prize winner Shinya Yamanaka

Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710

April 10, 2011 11:33 pm | by Bio-Medicine.Org | News | Comments

WHITEHOUSE STATION, N.J., and VIENNA, April 11, 2011 /- Merck (NYSE: MRK ), known as MSD outside the United States and Canada, and Intercell AG (VSE: ICLL) today announced that following a pre-specified interim analysis from the Phase II/III clinical trial evaluating V710, an...

Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema

April 7, 2011 11:34 pm | by Bio-Medicine.Org | News | Comments

TARRYTOWN, N.Y. and BERLIN, April 8, 2011 /- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Bayer HealthCare today announced that they have initiated the first of two Phase 3 clinical trials evaluating the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic solution), an...

Study Highlights Successes of Ascension Health Quality Initiative

April 7, 2011 8:38 am | by Bio-Medicine.Org | News | Comments

ST. LOUIS, April 7, 2011 /- A study published in the journal Health Affairs documents Ascension Health, the nation's third-largest health system, has achieved remarkable results in eliminating preventable mortality, lowering birth trauma rates, reducing bed sores and keeping patients...

NewCardio Study Shows my3KG Improves Diagnostic Accuracy in Diabetics With Acute Myocardial Infarction

April 7, 2011 5:33 am | by Bio-Medicine.Org | News | Comments

SANTA CLARA, Calif., April 7, 2011 /- PR Newswire – NewCardio, Inc., (OTC BB: NWCI) a cardiac diagnostic technology provider, announced today that the Company has been invited by the American Diabetes Association (ADA) to present the results of a key study showing that NewCardio's...

Cellular Dynamics Raises $30 Million to Expand Its Product Line of Human Stem Cells and Tissue Cells

April 7, 2011 2:34 am | by Bio-Medicine.Org | News | Comments

MADISON, Wis., April 7, 2011 /- Cellular Dynamics International, Inc. (CDI), the world's only industrial manufacturer of human induced pluripotent stem cells (iPSCs) and tissue cells, has closed on a $30 million private equity round. This recent Series B Preferred Stock financing was led...

Bloxx Provides Peterborough & Stamford Hospitals NHS Foundation Trust with Cost-Effective and Superior Web Filtering

April 6, 2011 1:34 am | by RealWire | News | Comments

Increased levels of user and network protection with lower total cost of ownership, simplified on-going management and reduced risk and liability delivered by real-time Web filteringBloxx, the innovator in Web and Email content filtering, today announced that Peterborough & Stamford...

Jennerex and Transgene Announce Presentation of Phase 1 Data Demonstrating that JX-594 Administration Targets Tumor Vasculature

April 5, 2011 10:34 pm | by Bio-Medicine.Org | News | Comments

SAN FRANCISCO and ILLKIRCH, France, April 6, 2011 /- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene (NYSE Euronext Paris: FR0005175080), a...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading